Roche Licenses Rona ALK7 RNAi Program
Roche obtained an exclusive worldwide license to Rona Therapeutics’ investigational ALK7-targeting RNA interference program for obesity and metabolic disease. Rona is eligible for up to $100 million in combined upfront and near-term milestone payments,…
